Summary.-Patients with advanced malignant disease show an apparent lesser degree of lymphocyte sensitization to cancer antigen when tested under standard conditions than do early cases. In the serum of cancer patients there is a lymphocyte response depressing factor whose titre rises as the neoplasm becomes more extensive. The low lymphocyte response shown by advanced cancers is not, however, directly referable to this rise in depressive factor, but to removal by the tumour mass of specifically sensitized lymphocytes so that amongst the standard number of cells under routine test an adequate number does not remain to give a full response. Increasing the number of cells under test restores the result to the level found in moderately sized cancers. The " absorptive capacity " of large tumours for circulating sensitized lymphocytes is greater than can be provided by natural immunization produced by the tumour. Active immunization with a tumour antigen can be expected therefore to increase lymphocyte -associated defence against cancer.
IT has previously been reported (Field and Caspary, 1970 ) that patients suffering from malignant neoplasia show lymphocyte sensitization to encephalitogenic factor (EF)-a low molecular weight basic protein isolated from human brain (Caspary and Field, 1965) and capable of producing allergic encephalomyelitis in guinea-pigs when injected (with Freund's complete adjuvant) in very small doses. Later it was found that a similar small protein antigen could be isolated from a variety of malignant tumours and that lymphocytes from patients with such tumours showed even higher sensitization to this than to EF . As our series of cases grew, it became apparent that patients with advanced malignant tumours in general gave lower results than did early ones. Under the stimulus of a similar observation by an independent group of workers (Joslin, Pritchard, Sutherland and Moore-private communication) a more detailed study of the phenomenon has been undertaken and is presented here. It emerges that in cancer a lymphocyte depressive factor (LDF) appears in the serum and rises markedly in titre as the tumour progresses. The occurrence of this factor may be a particular instance of a general phenomenon which accompanies lymphocyte sensitization though its biological significance is uncertain. However, the part played by LDF in producing the low observed values in advanced cancers is not clear, since there is also evidence that a large tumour mass filters target-sensitized cells out of the circulation, leaving insufficient numbers in the blood to give the considerably higher result shown by smaller tumours under the standard conditions of test.
MATERIALS AND METHODS
Studies have been carried out on 17 patients with advanced carcinoma and on a further 37 patients with moderately advanced or early tumour by the macrophage electrophoresis method described in extenso Caspary, 1970, 1971; Caspary and Field, 1971) , but orientated towards eliciting the reason for the tendency to low values in advanced malignancy. For comparison, 13 subjects with non-malignant or " premalignant" disease have also been studied.
In principle, the method depends upon interaction of antigen with sensitized lymphocytes to liberate a protein (Caspary, 1971) with the property of causing normal macrophages to travel more slowly in an electric field (macrophage slowing factor-MSF). This factor may be identical with macrophage migration inhibitory factor (MIF). Normal guinea-pig macrophages are thus used as an indicator system to detect antigenlymphocyte interaction. In practice, normal guinea-pig macrophage exudate is raised by intraperitoneal inoculation of sterile liquid paraffin and harvesting the cells 8-16 days later. This exudate contains 10-20% of lymphocytes and since these may enter into a mixed" reaction when brought into contact with human lymphocytes, the exudate is exposed to 100 rad of y-irradiation from a Cobalt bomb which incapacitates-at least temporarily-the guinea-pig lymphocytes Hughes and Paty, 1972) . It should be noted that 100 rad is effective only against unsensitized lymphocytes. If, however, the guinea-pig lymphocytes are sensitized then even 500 rad w%Aill not abolish their reactivity. This has been found by direct experiment.
Lymphocytes are prepared from about 18 ml of venous blood by removing polymorphs w-ith carbonyl iron and methyl cellulose (Hughes and Caspary, 1970) . In carrying out a routine test, 0.5 x 106 lymphocytes from the patient are mixed with 107 irradiated normal guinea-pig macrophages in medium 199 and incubated without addition of antigen for 90 minutes at 20°C. In other experiments, where the effect of making available a larger number of sensitized cells was to be studied, 2-5 or 5 0 million lymphocytes have been used. The migration speed of the macrophages is then estimated and constitutes the control time. To other mixtures of lymphocytes and macrophages the antigens to be tested are added-usually at 33 yig/ml final concentration. Antigens used in this study have been PPD-purified protein derivative of tubercle; encephalitogenic factor (EF)-a small basic protein prepared from normal human brain (Caspary and Field, 1965) , measles virus (grown in LLC-MK2 cells), and a number of antigens prepared in the same way from different human tumours, especially one from a cancer of the cervix . After incubation, the time of macrophage migration is again estimated. all measurements being made " blind ", i.e. the specimens numbered and the results later decoded. For each assessment, 10 cells are timed in both directions of the potential difference in a Zeiss cytopherometer. A complete account-with a detailed original protocol-has been presented by Caspary and Field (1971 ciated with sarcoidosis 9-3 13-3 15-5 6-3 9-9 12-6 10-1 12-7 14-9 8-1 13-9 15-6 
DISCUSSION
The occurrence of a lymphocyte reactivity depressive factor (LDF) in serum was noted by Kamrin (1959) whilst Mowbray (1963a, b) and Mowbray and Hargrave (1966) found that a serum factor could diminish antibody response in experimental animals. Cooperband et al. (1968) (Heilman and MacFarland, 1966) ; hepatitis (Paronetto and Popper, 1970) ; ataxia telangiectasia (MacFarlin and Oppenheim, 1969) ; secondary syphilis (Levene et al., 1969) ; chronic candidiasis (Canales et al., 1969) ; Hodgkin's disease (Trubowitz, Masek and del Rosario, 1966) ; as well as cancer (Trubowitz et al., 1966; Salk, 1967; and others) . With the present highly sensitive and quantitative method of assessing lymphocyte sensitization, the titre of LDF in health and disease can readily be determined. It appears that elevation of the level of LDF is an invariable concomitant of special lymphocyte sensitization and might constitute a " braking mechanism " built into the cellular immunological response to antigen. Whilst in some conditions studied (neurological disease, sarcoidosis) the serum is active at high dilution against own cells rather than against those of another patient with the same condition , so that in a sense it is " tailor made " to its own lymphocytes, this is not apparent in the case of advanced cancer where, if anything, a serum seems rather more active in the homologous situation than the autologous (Tables Ila, b) . Whilst no satisfactory explanation can be offered for this difference, it may be associated with the continuous and active new antigenic stimulation in cancer. Apart from malignant neoplasia LDF may allow a fine regulation to be achieved by means of an " accelerator-brake " mechanism, bringing, however, in its train the possibility of imbalance leading to disease states. Thus failure of adequate LDF production or function might result in runaway aggression by lymphocytes which have become sensitized, for one reason or another, to a constituent of a target organ. If further study supports this view in a disease, for example, like multiple sclerosis, then elevation of LDF would be a rational therapy. On the other hand, a mechanism which has been evolved to damp down reaction to transient and biologically unimportant antigens-e.g. as may occur in banal infections-may swing into action in a situation where maximum lymphocyte reactivity would be beneficial. One such situation is defence against cancer. Under these conditions it would be reasonable to direct therapy towards lowering the level of LDF so that lymphocyte activity towards the cancer is unhindered. The negative correlation between the degree of lymphocyte sensitization (as measured in 0.5 million cells) and LDF is very high, both in the autologous and homologous situations. Despite this, the biological significance of this correlation in cancer is dubious for the following reasons: Normally 0-5 x 106 lymphocytes are used in the test as usually carried out. If, however, the number is raised five-fold to 2-5 X 106 then the previously low value in advanced cancer rises to the expected 15% or so. The simplest interpretation is that the large tumour mass " sponges up " so many sensitized lymphocytes from the circulation that an inadequate number remains amongst 0 5 x 106 cells to give a full result. Whilst the tumour continues to sensitize more lymphocytes, its absorptive capacity outstrips its immunizing ability. If this is the true interpretation, then it supports the view that further active immunization would raise the number of sensitized (defensive) lymphocytes and offers encouragement for immunization therapy as an effective treatment of cancer.
Increasing the number of lymphocytes when testing with measles antigen does not increase the result in cancer patients (Table III) . As would be expected in the absence of a " sponging up " process from the circulation, the half million is adequate to give a maximal result. In the few cases so far tested, the result is raised if the number of cells used is increased when PPD is the antigen. A systematic study of cellular sensitization to PPD in advanced cancer is now in progress using 0.5, 2-5 and 5-0 X 106 cells. It is known that PPD shares antigenic determinants with encephalitogenic factor (EF) derived from human brain (Field et al., 1963) and that cancer basic protein, EF and PPD are antigenically related, PPD being further removed from cancer antigen than is EF (Field, Caspary and Carnegie, 1971) . This antigenic relationship between PPD and cancer antigen would mean that PPD sensitized cells might also be " sponged up " by a large tumour mass and that the result obtained, when lymphocyte sensitization to PPD is tested for, will be greater if a large number of cells is used. This might explain, too, the apparent success of BCG immunotherapy in acute lymphoblastic leukaemia claimed by Mathe et al. (1969) and usually attributed to " nonspecific " stimulation of the lymphocytic defensive system. In the present interpretation such immunization would increase the number of cells sensitized to the neoplastic tissue, for BCG would not be a " nonspecific " antigen but a specific one-albeit probably not the best which can be made.
In advanced pregnancy where the result with 0 5 x 106 cells is low, stepping up the number to 2-5 X 106 has no effect. It would appear then that amongst such cases the response is maximal with 0-5 x 106 cells and that the depression in pregnancy may reside in the cells themselves or be due to LDF (Smith et al., 1972) and is not due to deficient number of cells.
An alternative explanation for the failure of 0 5 million cells to give a full response whereas 2.5 millions do so, might be depressed reactivity of those lymphocytes which are sensitized to tumour antigen. Whilst the evidence is to some extent contradictory (Gatti, Garrioch and Good, 1970) , perhaps on account of technical differences, the majority of workers have reported no difference in the ability of lymphocytes in (nonlymphoproliferative) neoplasia to respond to PHA stimulation (e.g. Robinson and Hurvitz, 1966; Benezra and Hochman, 1971; and others) . Some of the discrepancies may well be due to inadequate washing of lymphocytes since LDF titre may on occasion be very high in advanced cancer (> 1: 7960) . Moreover, there is some evidence that cells which are sensitized to tumour antigen are stimulated even more by PHA (Chu et al., 1967; Frenster and Rogoway, 1970 It is clear that elevated LDF levels can coexist with increased lymphocyte sensitization. This is seen in early and moderately advanced malignant neoplasia and in conditions such as sarcoidosis . Whilst LDF may not be important in producing the low sensitization values found in advanced cancer, it may be significant under more physiological conditions. Here low results are not due to inadequate numbers of PPD sensitized cells in the standard 0 5 million used. Lymphocyte reactivity to PPD during pregnancy-especially as it advances-is reduced, to be restored within about 8 days of delivery. At the same time, LDF presents a rise during pregnancy and a return to normal in the puerperium (Smith et al., 1972) . It should be noted that the low results in advanced pregnancy are obtained in medium 199, i.e. the high LDF serum is excluded from the system, yet the low reactivity of the cells persists. Whether prolonged in vivo exposure to LDF " switches off" the cells (to be made reactive again in the puerperium, perhaps under some hormonal influence) or there is simply low intrinsic reactivity in advanced pregnancy remains to be determined.
Finally, the possibility must also be entertained that LDF may play a part in the complex homoeostatic situation which occurs in long-term cancer. It seems possible that dissemination of cancer cells occurs in many instances, perhaps in the large majority of patients, and is responsible for the very prolonged maintenance of a clone of cancer sensitized lymphocytes even after apparent surgical eradication Field, 1972) . Immunosurveillance of small foci of cancer cells (Burnett, 1969) depends upon the activity of lymphocytes, which in turn is balanced against LDF of serum. Elevation of LDF from some extraneous cause might upset a long maintained equilibrium, with escape of the malignant cell nest from controls, and so allow the development of a late "secondary " growth.
